Expected outcomes and patients’ selection before chemoembolization—“Six-and-Twelve or Pre-TACE-Predict” scores may help clinicians: Real-life French cohorts results

Figure 1 Patients’ allocation and survival according to scoring systems in cohort 1 (recommended transarterial chemoembolization patients). NIACE: Number of tumor(s), Infiltrative hepatocellular carcinoma, Alpha-fetoprotein, Child-Pugh class, Eastern Cooperative Oncology Group Performance Status; 6&12: “Six-and-Twelve”; ALBI: Albumin-Bilirubin; NS: Not significant; G: Grade; C: Category; TACE: Transarterial chemoembolization.

Figure 2 Kaplan-Meier analysis of overall survival according to “pre-transarterial chemoembolization-predict” model in the multicenter French hepatocellular carcinoma cohort (n = 324). C: Category.

Figure 3 Patients’ allocation and survival according to scoring systems in cohort 2 (intermediate/advanced stage hepatocellular carcinomas). NIACE: Number of tumor(s), Infiltrative hepatocellular carcinoma, Alpha-fetoprotein, Child-Pugh class, Eastern Cooperative Oncology Group Performance Status; 6&12: “Six-and-Twelve”; ALBI: Albumin-Bilirubin; NS: Not significant; G: Grade; C: Category; TACE: Transarterial chemoembolization.

Figure 4 Summary of the study (patients' stratification according to the newly proposed scoring systems: “6 and 12” and “Pre-TACE-Predict”). TACE: Transarterial chemoembolization; PS: Performance status; PVT: Portal vein thrombosis; EHS: Extra-hepatic spread; “6&12”: “Six-and-Twelve”; cTACE: Conventional transarterial chemoembolization; OS: Overall survival; ICIs: Immune checkpoint inhibitors.